Canton Strategic Holdings (CNTN) Gains from Investment Securities (2020 - 2026)
Canton Strategic Holdings (CNTN) reported Gains from Investment Securities of $656163.0 for Q1 2026, up 170.26% on a YoY basis from $242788.0 in Q1 2025, and little changed quarter-over-quarter from $657042.0 in Q4 2025.
Canton Strategic Holdings (CNTN) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Gains from Investment Securities for 7 years, with the latest figure at $656163.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 170.26% year-over-year to $656163.0; the trailing twelve-month figure through Mar 2026 stood at $656163.0 (up 170.26% YoY), and the FY2025 full-year result was $657042.0, up 503.04% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $656163.0, roughly flat from $657042.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $657042.0 in Q4 2025, with the low at $582.0 in Q2 2025.
- Historically, Gains from Investment Securities has averaged $230359.9 across 5 years, with a median of $61579.5 in 2022.
- The largest YoY upside for Gains from Investment Securities was 13042.28% in 2025 against a maximum downside of 90.46% in 2025.
- Canton Strategic Holdings' Gains from Investment Securities stood at $14204.0 in 2022, then plunged by 57.04% to $6102.0 in 2023, then jumped by 1685.56% to $108955.0 in 2024, then surged by 503.04% to $657042.0 in 2025, then fell by 0.13% to $656163.0 in 2026.
- The last three Gains from Investment Securities figures came in at $656163.0 (Q1 2026), $657042.0 (Q4 2025), and $607042.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 656,163.00 |
| Mar 31, 2026 | 656,163.00 |
| Dec 31, 2025 | 657,042.00 |
| Dec 31, 2025 | 657,042.00 |
| Sep 30, 2025 | 607,042.00 |
| Sep 30, 2025 | 607,042.00 |
| Jun 30, 2025 | 582.00 |
| Jun 30, 2025 | 582.00 |
| Mar 31, 2025 | 242,788.00 |
| Mar 31, 2025 | 242,788.00 |
| Dec 31, 2024 | 108,955.00 |
| Dec 31, 2024 | 108,955.00 |
| Sep 30, 2024 | 4,619.00 |
| Sep 30, 2024 | 4,619.00 |
| Jun 30, 2024 | 6,102.00 |
| Jun 30, 2024 | 6,102.00 |
| Dec 31, 2023 | 6,102.00 |
| Dec 31, 2023 | 6,102.00 |
| Mar 31, 2022 | 14,204.00 |
| Mar 31, 2022 | 14,204.00 |